We believe ibrexafungerp has the potential to prevent recurrent vaginal yeast infections, also known as recurrent vulvovaginal candidiasis (VVC), across a broad range of patients for whom current treatment options are suboptimal. Despite yeast infections being so common, with millions of women suffering from them every year, recurrent VVC is still an under-appreciated, under-reported, and under-served women’s health condition.
- Dr. Jack D. Sobel
Current Infectious Disease Reports 2006,8:481–486
(Ibrexafungerp is not approved for the prevention of recurrent VVC.)
The CANDLE Phase 3 Study (ongoing) for the Prevention of Recurrent VVC
In March 2021, we completed enrollment in the CANDLE study (ClinicalTrials.gov identifier: NCT04029116).